31 results match your criteria Clinical Medicine Insights: Blood Disorders [Journal]

  • Page 1 of 1

Diffuse Large B-Cell Lymphoma Relapsing in Leukaemic Phase Presenting as Acute Leukaemia.

Clin Med Insights Blood Disord 2019 15;12:1179545X18821160. Epub 2019 Jan 15.

Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, New Delhi, India.

Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of the newly diagnosed adult non-Hodgkin lymphomas, but rarely presents in leukaemic phase. Here in, we report a case of DLBCL presenting in leukaemic phase and masquerading as acute leukaemia. A 28-year-old woman presented to our outpatient department with complaints of fever for 1 week. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X18821160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343450PMC
January 2019
2 Reads

Routine Preoperative Coagulation Tests in Children Undergoing Elective Surgery or Invasive Procedures: Are They Still Necessary?

Clin Med Insights Blood Disord 2019 5;12:1179545X18821158. Epub 2019 Jan 5.

Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Introduction: Preoperative coagulation screening tests in pediatric patients was once routine clinical practice globally and still used as standard practice in some countries before surgical procedures to assess of perioperative bleeding risk.

Objective: The study aimed to evaluate unselected routine preoperative coagulation testing in children undergoing elective or invasive surgery to predict abnormal perioperative bleeding. The study also aimed to provide a rational approach of determining bleeding and family history of coagulation disorders as a predictive risk for bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X18821158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322095PMC
January 2019
5 Reads

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization.

Clin Med Insights Blood Disord 2018 30;11:1179545X18792253. Epub 2018 Aug 30.

Department of Medicine, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX, USA.

Background: When used for hematopoietic stem cell mobilization, plerixafor was originally recommended to be administered 11 hours prior to apheresis based on the peak effect of 10 to 14 hours translating into an administration time of 10 to 11 pm. Reports of post-plerixafor anaphylactic reactions mandated labeling change by the Food and Drug Administration with recommendation of monitoring patients after administration. Based on data suggesting sustained plerixafor activity at 18 hours, we changed our administration time to 4 pm at our center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X18792253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120178PMC
August 2018
32 Reads

The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Clin Med Insights Blood Disord 2018 26;11:1179545X18762799. Epub 2018 Mar 26.

Division of Hematology, University of Washington, Seattle, WA, USA.

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant of DLBCL. The natural history of this subtype is poorly understood. Incomplete literature in the era of rituximab suggests that patients with EBV-positive DLBCL have similar outcomes to patients with EBV-negative DLBCL when treated with rituximab and anthracycline-based chemotherapy regimens; however, there are few prospective studies on this subtype and little is known about the risk of central nervous system (CNS) relapse with EBV-positive DLBCL. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1179545X18762799
Publisher Site
http://dx.doi.org/10.1177/1179545X18762799DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881979PMC
March 2018
6 Reads

Preeclampsia: From Inflammation to Immunoregulation.

Clin Med Insights Blood Disord 2018 10;11:1179545X17752325. Epub 2018 Jan 10.

Departments of Emergency Medicine and Pharmacology and Toxicology, The University of Mississippi Medical Center, Jackson, MS, USA.

Preeclampsia (PE) affects 5% to 7% of pregnant women each year worldwide, accounts for up to 18% of maternal deaths in the United States each year, and is the number 1 cause of premature births. Preeclampsia is associated with hypertension after the 20th week of gestation with or without proteinuria, in conjunction with fetal growth restriction, maternal endothelial dysfunction, and chronic immune activation. The mechanisms leading to the development of PE are unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17752325DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772493PMC
January 2018
5 Reads

Effect of the Ginger Derivative, 6-Shogaol, on Ferritin Levels in Patients With Low to Intermediate-1-Risk Myelodysplastic Syndrome-A Small, Investigative Study.

Clin Med Insights Blood Disord 2017 2;10:1179545X17738755. Epub 2017 Nov 2.

American Medical Holdings Inc., New York, NY, USA.

Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders characterized by dysplastic and ineffective hematopoiesis and peripheral cytopenias. Elevated serum ferritin (SF) is often observed in nontransfused, lower risk MDS. It has been reported that ineffective erythropoiesis enhances iron absorption in MDS through downregulation of hepcidin and its prohormones such that SF rises. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17738755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673003PMC
November 2017
8 Reads

Diffuse Large B-Cell Breast Lymphoma: A Case Series.

Clin Med Insights Blood Disord 2017 14;10:1179545X17725034. Epub 2017 Aug 14.

Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.

Primary breast lymphoma (PBL) is a rare disease, and few clinicohistopathologic features of the disease have been discussed in previous studies. It represents 2.2% of extranodal lymphomas and constitutes 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17725034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560510PMC
August 2017
18 Reads

Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.

Clin Med Insights Blood Disord 2017 24;10:1179545X17705863. Epub 2017 Apr 24.

Department of Clinical Haematology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals, Oxford, UK.

T-cell and natural killer-cell lymphomas are a relatively rare and heterogeneous group of diseases that are difficult to treat and usually have poor outcomes. To date, therapeutic interventions are of limited efficacy and there is a pressing need to find better treatments. In recent years, advances in molecular biology have helped to elucidate the underlying genetic complexity of this group of diseases and to identify mutations and signaling pathways involved in lymphomagenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17705863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428136PMC
April 2017
8 Reads

Estimation of Platelet Counts and Other Hematological Parameters in Pseudothrombocytopenia Using Alternative Anticoagulant: Magnesium Sulfate.

Clin Med Insights Blood Disord 2017 24;10:1179545X17705380. Epub 2017 Apr 24.

Department of Pathology, Chettinad Medical College, Kelambakkam, India.

The platelet count, mean platelet volume, and other hematological parameters were compared in blood samples anticoagulated with MgSO and EDTA. A total of 15 samples were taken, and the platelet counts were observed to be significantly high in MgSO-anticoagulated blood samples ranging from 53 × 10 to 499 × 10/μL, whereas in EDTA-anticoagulated blood samples, the counts ranged from 10 × 10 to 353 × 10/μL. This increased platelet count was also statistically significant with the value being . Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1179545X17705380
Publisher Site
http://dx.doi.org/10.1177/1179545X17705380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428203PMC
April 2017
7 Reads

Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.

Clin Med Insights Blood Disord 2017 8;10:1179545X17704660. Epub 2017 May 8.

Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Background: Venous thromboembolism (VTE) is a potentially fatal complication of orthopedic surgery, and until recently, few antithrombotic compounds were available for postoperative thromboprophylaxis. The introduction of the non-vitamin K antagonists oral anticoagulants (NOAC), including apixaban, has extended the therapeutic armamentarium in this field. Therefore, estimation of NOAC net clinical benefit in comparison with the established treatment is needed to inform clinical decision making. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1179545X17704660
Publisher Site
http://dx.doi.org/10.1177/1179545X17704660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428133PMC
May 2017
56 Reads
2 Citations

Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature.

Clin Med Insights Blood Disord 2017 30;10:1179545X17700858. Epub 2017 Mar 30.

Department of Hematology/Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Systemic mastocytosis (SM) is a condition associated with clonal neoplastic proliferation of mast cells. In up to 40% of systemic mastocytosis cases, an associated clonal hematological disease of non-mast cell lineage, such as acute myeloid leukemia (AML), is diagnosed before, simultaneously with, or after the diagnosis of SM. Herein, we report a case of a 30-year-old man diagnosed with AML with inv(16) (p13;q22) CBFB:MYH11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17700858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428180PMC
March 2017
57 Reads

Kasabach-Merritt Phenomenon: Classic Presentation and Management Options.

Clin Med Insights Blood Disord 2017 16;10:1179545X17699849. Epub 2017 Mar 16.

Department of Pediatrics, Baylor College of Medicine, Vascular Anomalies Center at Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX, USA.

Kasabach-Merritt phenomenon (KMP) is a rare consumptive coagulopathy associated with specific vascular tumors, kaposiform hemangioendothelioma, and tufted angioma. Kasabach-Merritt phenomenon, characterized by profound thrombocytopenia, hypofibrinogenemia, elevated fibrin split products, and rapid tumor growth, can be life-threatening. Severe symptomatic anemia may also be present. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17699849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428202PMC
March 2017
10 Reads

Treatment of Myelofibrosis: Old and New Strategies.

Clin Med Insights Blood Disord 2017 8;10:1179545X17695233. Epub 2017 Mar 8.

Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy.

Myelofibrosis (MF) is a -negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of mutations has also led to the development of small-molecule / inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17695233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428134PMC
March 2017
45 Reads

Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.

Clin Med Insights Blood Disord 2017 28;10:1179545X17692544. Epub 2017 Feb 28.

Department of Hematology and Oncology, Virginia Mason Medical Center, Seattle, WA, USA.

Most commonly, histologic transformation (HT) from follicular lymphoma (FL) manifests as a diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Less frequently, HT may result in a high-grade B-cell lymphoma (HGBL) with MYC and B-cell lymphoma protein 2 (BCL2) and/or BCL6 gene rearrangements, also known as "double-hit" or "triple-hit" lymphomas. In the 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms, the category B-cell lymphoma, unclassifiable was eliminated due to its vague criteria and limiting diagnostic benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X17692544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428247PMC
February 2017
59 Reads

Coexisting Sickle Cell Anemia and Sarcoidosis: A Management Conundrum!

Clin Med Insights Blood Disord 2017 28;10:1179545X16685314. Epub 2017 Feb 28.

Howard County General Hospital, USA.

Sickle cell disease and Sarcoidosis are conditions that are more common in the African American population. In this report we share an unfortunate patient who had hepatic sarcoidosis but could not receive steroids since that precipitated acute liver failure. We have discussed potential therapy options but we need more options that improve mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X16685314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428084PMC
February 2017
67 Reads

Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility.

Clin Med Insights Blood Disord 2016 27;9:33-41. Epub 2016 Oct 27.

Department of Medical Biotechnology, Laboratory of Microbiology and Immunology of Infectious Diseases, Paramedicine Faculty, Guilan University of Medical Sciences Rasht, Iran.

The 21st century is challenging for human beings. Increased population growth, population aging, generation of new infectious agents, and natural disasters are some threatening factors for the current state of blood transfusion. However, it seems that science and technology not only could overcome these challenges but also would turn many human dreams to reality in this regard. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S38461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084831PMC
October 2016
19 Reads

Low-Dose PET/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas.

Clin Med Insights Blood Disord 2016 17;9:29-32. Epub 2016 Aug 17.

PET Unit, IDI, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Computed tomography (CT) has been used as the reference imaging technique for the initial staging of diffuse large B-cell lymphoma until recent days, when the introduction of positron emission tomography (PET)/CT imaging as a hybrid technique has become of routine use. However, the performance of both examinations is still common. The aim of this work was to compare the findings between low-dose 2-deoxy-2-((18)F)fluoro-d-glucose ((18)F-FDG) PET/CT and full-dose contrast-enhanced CT (ceCT) in 28 patients with localized diffuse large B-cell lymphoma according to PET/CT findings, in order to avoid the performance of ceCT. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.4137/CMBD.S38468
Publisher Site
http://dx.doi.org/10.4137/CMBD.S38468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990149PMC
August 2016
20 Reads

Concomitant Classic Hodgkin Lymphoma of Lymph Node and cMYC-Positive Burkitt Leukemia/Lymphoma of the Bone Marrow Presented Concurrently at the Time of Presentation: A Rare Combination of Discordant Lymphomas.

Clin Med Insights Blood Disord 2016 3;9:23-8. Epub 2016 Aug 3.

Department of Hematology and Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Discordant lymphoma is rare condition in which different types of malignant lymphomas occurring in different anatomic sites. The two diseases may present clinically as concurrent or sequential disease (10). Herein we are reporting a Pakistani female in her 60s, a carrier of hepatitis B virus with multiple comorbidities presented with cervical lymphadenopathy, diagnosed as Hodgkin's lymphoma, mixed cellularity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S39908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973772PMC
August 2016
37 Reads

Advances in Diagnosis and Treatments for Immune Thrombocytopenia.

Authors:
Shosaku Nomura

Clin Med Insights Blood Disord 2016 17;9:15-22. Epub 2016 Jul 17.

First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.

Immune thrombocytopenia (ITP) is an acquired hemorrhagic condition characterized by the accelerated clearance of platelets caused by antiplatelet autoantibodies. A platelet count in peripheral blood <100 × 10(9)/L is the most important criterion for the diagnosis of ITP. However, the platelet count is not the sole diagnostic criterion, and the diagnosis of ITP is dependent on additional findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S39643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948655PMC
July 2016
16 Reads

Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival.

Clin Med Insights Blood Disord 2016 20;9:9-13. Epub 2016 Jun 20.

Department of Hematology and Immunology, Obafemi Awolowo University, Ile-Ife, Nigeria.; Department of Hematology and Blood Transfusion, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.

Objectives: The advent of the tyrosine kinase inhibitors has markedly changed the prognostic outlook for patients with Ph(+) and/or BCR-ABL1 (+) chronic myeloid leukemia (CML). This study was designed to assess the overall survival (OS) of Nigerian patients with CML receiving imatinib therapy and to identify the significant predictors of OS.

Methods: All patients with CML receiving imatinib from July 2003 to June 2013 were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S31562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915783PMC
July 2016
17 Reads

Pediatric Blood Pressure and Adult Preclinical Markers of Cardiovascular Disease.

Clin Med Insights Blood Disord 2016 4;9:1-8. Epub 2016 May 4.

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

A high blood pressure level in adults is considered the single most important modifiable risk factor for global disease burden, especially those of cardiovascular (CV) origin such as stroke and ischemic heart disease. Because blood pressure levels have been shown to persist from childhood to adulthood, elevations in pediatric levels have been hypothesized to lead to increased CV burden in adulthood and, as such, might provide a window in the life course where primordial and primary prevention could be focused. In the absence of substantive data directly linking childhood blood pressure levels to overt adult CV disease, this review outlines the available literature that examines the association between pediatric blood pressure and adult preclinical markers of CV disease. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.4137/CMBD.S18887
Publisher Site
http://dx.doi.org/10.4137/CMBD.S18887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857790PMC
May 2016
40 Reads

Mixed Phenotype Acute Leukemia with Two Immunophenotypically Distinct B and T Blasts Populations, Double Ph (+) Chromosome and Complex Karyotype: Report of an Unusual Case.

Clin Med Insights Blood Disord 2015 21;8:25-31. Epub 2015 Sep 21.

Department of Haematology and Medical Oncology, Hamad Medical Corporation, Doha, Qatar.

Mixed phenotype acute leukemia (MPAL) is considered as a rare type of leukemia with an incidence of less than 4% of all acute leukemia based on the most recent 2008 WHO classification. Common subtypes are the B/myeloid and T/myeloid; B/T and trilineage MPAL being extremely rare. We present a case of a male in his 20s, whose peripheral blood smears showed 34% blast cells and bone marrow with 70% blasts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S24631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578553PMC
October 2015
20 Reads

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia.

Clin Med Insights Blood Disord 2015 23;8:19-23. Epub 2015 Jul 23.

Qatar Medical Genetic Center, Hamad Medical Corporation, Doha, Qatar.

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia (Ph) chromosome resulting from the reciprocal translocation t(9;22)(q34;q11). The molecular consequence of this translocation is the generation of the BCR-ABL fusion gene, which encodes a constitutively active protein tyrosine kinase. The oncogenic protein tyrosine kinase, which is located in the cytoplasm, is responsible for the leukemia phenotype through the constitutive activation of multiple signaling pathways involved in the cell cycle and in adhesion and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S24628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514172PMC
August 2015
21 Reads

Anemia and the Need for Intravenous Iron Infusion after Roux-en-Y Gastric Bypass.

Clin Med Insights Blood Disord 2015 4;8:9-17. Epub 2015 Jun 4.

Division of Hematology/Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.

The frequency of anemia, iron deficiency, and the long-term need for IV iron following Roux-en-y gastric bypass (RYGB) surgery has not been well characterized. Three-hundred and nineteen out of 904 consecutive subjects who underwent RYGB at Penn State Hershey Medical Center from 1999 to 2006 met the inclusion criteria for a preoperative complete blood count (CBC) and at least one CBC >6 months following surgery. Cumulative incidence of anemia 7 years post procedure was 58%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S21825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462165PMC
June 2015
16 Reads

Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.

Clin Med Insights Blood Disord 2015 24;8:1-7. Epub 2015 May 24.

Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Objective: Idiopathic thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder mediated by autoantibodies directed against ADAMTS13. This provides a rationale for the use of rituximab in this disorder. We report our experience and the outcome of 10 cases of TTP (9 refractory and 1 relapsing) successfully treated with rituximab in combination with plasma exchange (PE) and other immunosuppressive treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S25326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451552PMC
June 2015
28 Reads

Ribosomopathies: mechanisms of disease.

Clin Med Insights Blood Disord 2014 14;7:7-16. Epub 2014 Aug 14.

Department of Biochemistry and Molecular Biology and Cancer Center, Tulane University, School of Medicine, New Orleans, Louisiana, LA, USA.

Ribosomopathies are diseases caused by alterations in the structure or function of ribosomal components. Progress in our understanding of the role of the ribosome in translational and transcriptional regulation has clarified the mechanisms of the ribosomopathies and the relationship between ribosomal dysfunction and other diseases, especially cancer. This review aims to discuss these topics with updated information. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.4137/CMBD.S16952
Publisher Site
http://dx.doi.org/10.4137/CMBD.S16952DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251057PMC
December 2014
22 Reads

Risk factors for thrombosis in an african population.

Clin Med Insights Blood Disord 2014 10;7:1-6. Epub 2014 Apr 10.

Laboratory of Hematology, Bicêtre Hospital of Paris, France.

Summary: Little is known about the biological, epidemiological, and clinical risk factors for thrombosis and venous thromboembolism (VTE) among Black Africans. We undertook a study of the prevalence of VTE risk factors for thrombosis in a Senegalese population. A three-year cross-sectional and case-control study involving 105 cases and 200 controls was conducted in various hospitals in Dakar (Senegal). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S13401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251055PMC
December 2014
11 Reads

Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.

Clin Med Insights Blood Disord 2013 14;6:23-7. Epub 2013 Nov 14.

Department of Hematology, L'Hospitalet, Barcelona, Spain.

Diffuse large b-cell lymphoma (DLBCL) is an aggressive and potentially curable lymphoma that presents itself as stage I-II in 30% of all cases. It is known that in these localized stages, 15-20% of patients treated without rituximab eventually relapse, but less data exist regarding rituximab era. We have analyzed clinico-pathological features and risk of relapse in 98 patients with I-II stage DLBCL in complete response (CR) or unconfirmed CR (CRu) after first-line treatment consisting of immunochemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S12713DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222304PMC
December 2014
7 Reads

Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura.

Clin Med Insights Blood Disord 2013 14;6:19-22. Epub 2013 Nov 14.

Department of Medicine, Division of Hematology/Oncology Sylvester Comprehensive Cancer Center, University of Miami, Leonard M. Miller School of Medicine, Miami, Florida.

A 21-year-old male presented to the emergency department after a 5-day history of recurrent vomiting and decreased urine output. History revealed ingestion of ibuprofen. During the diagnostic workup, the following was identified: white blood cell count 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S12843DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222303PMC
December 2014
30 Reads

Hemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria.

Clin Med Insights Blood Disord 2013 20;6:7-17. Epub 2013 Jun 20.

Assistant Professor of Medicine, Department of Medicine, UMass Memorial Medical Center, Worcester, MA.

Discolored urine is a common reason for office visits to a primary care physician and urology referral. Early differentiation of the type or cause of discolored urine is necessary for accurate diagnosis and prompt management. Paroxysmal nocturnal hemoglobinuria is a clonal disorder caused by acquired somatic mutations in the PIG-A gene on the X- chromosome of hemopoietic stem cells and leads to deficiency of surface membrane anchor proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S11517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222305PMC
December 2014
6 Reads

Idiopathic thrombocytopenia with iron deficiency anemia.

Clin Med Insights Blood Disord 2013 14;6:1-5. Epub 2013 Apr 14.

Brookdale University Hospital and Medical Center, Brooklyn, NY.

We report a rare case of anemia and thrombocytopenia as a result of uterine fibroid and adenomyosis, complicated by immune thrombocytopenic purpura (ITP). Symptoms were presented as menorrhagia and metrorrhagia in a 34-year-old African American woman, who was later treated with blood and platelet transfusion and iron therapy with steroids. Uterine fibroids are commonly found to cause hematologic disturbances such as anemia and reactive thrombocytosis and, less commonly, thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMBD.S11371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222302PMC
December 2014
19 Reads
  • Page 1 of 1